PARP inhibitor

PARP inhibitors are a group of pharmacologicalinhibitors of the enzyme poly ADP ribose polymerase (PARP). They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.

Mechanism of action

DNA is damaged thousands of times during each cell cycle, and that damage must be repaired.

BRCA1, BRCA2 and PALB2 are proteins that are important for the repair of double-strand DNA breaks by the error-free homologous recombinational repair, or HRR, pathway. When the gene for either protein is mutated, the change can lead to errors in DNA repair that can eventually cause breast cancer. When subjected to enough damage at one time, the altered gene can cause the death of the cells.

PARP inhibitor

PARP inhibitors are a group of pharmacologicalinhibitors of the enzyme poly ADP ribose polymerase (PARP). They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.

Mechanism of action

DNA is damaged thousands of times during each cell cycle, and that damage must be repaired.

BRCA1, BRCA2 and PALB2 are proteins that are important for the repair of double-strand DNA breaks by the error-free homologous recombinational repair, or HRR, pathway. When the gene for either protein is mutated, the change can lead to errors in DNA repair that can eventually cause breast cancer. When subjected to enough damage at one time, the altered gene can cause the death of the cells.

Latest News for: parp inhibitor

JAVELIN Ovarian PARP100 is a randomized, open-label, multicenter PhaseIII study of avelumab plus chemotherapy followed by maintenance therapy of avelumab in combination with a PARPinhibitor or chemotherapy followed by maintenance therapy with a PARPinhibitor, in patients with previously untreated advanced ovarian cancer....

Tesaro's lead ovarian cancer drug, Zejula, competes with Clovis Oncology Inc's Rubraca and AstraZeneca's Lynparza - all of which belong to a closely watched class of new medicines called PARPinhibitors... ....

This trial was designed to evaluate the potential synergies between DNA damaging therapies and/or agents and our investigational PARPinhibitor, pamiparib, which in pre-clinical studies has demonstrated brain penetration and PARP trapping activity....

We are pleased that the Phase 1B/2 clinical study evaluating sapacitabine in combination with the approved PARPinhibitor olaparib or AstraZeneca's Lynparza has started enrollments of BRCA positive patients with breast cancer ... Sapacitabine works by HRD relevant mechanism that is distinct from the MOA of PARPinhibitors....

Since launched in April 2017, Zejula is the most prescribed PARPinhibitor (as a maintenance therapy for patients afflicted by ovarian cancer in the U.S., who demonstrated the complete or partial responses to platinum-based chemotherapy)....

This is the first regulatory submission acceptance for a poly ADP-ribose polymerase (PARP) inhibitor in the advanced ovarian cancer 1st-line maintenance setting, and if approved will be the fourth indication for LYNPARZA in the US ... LYNPARZA is a first-in-class poly ADP-ribose polymerase (PARP) inhibitor approved in the US since 2014....

regulatory submission acceptance for a poly ADP-ribose polymerase (PARP) inhibitor in the first-line maintenance setting for advanced ovarian cancer, and, if approved, will be the fourth indication for LYNPARZA in the U.S ... LYNPARZA is a first-in-class PARPinhibitor approved in the U.S....

SALT LAKE CITY, Nov ... (NASDAQ ... 4-8, 2018 in San Antonio, Tx ... About myChoice HRD ™Myriad's myChoice HRD is the first homologous recombination deficiency test that can detect when a tumor has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARPinhibitors ... ....

We also announced two clinical collaborations to evaluate Pfizer's CDK4/6 palbociclib, also known as IBRANCE; and the dual mechanism PARPinhibitor talazoparib, also known as TALZENNA, each in combination with our glutaminase inhibitor CB-839 ... which is a PARPinhibitor....